Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$332.15 1.03 (0.31)%

High 341.08 Low 328.95 Volume 1,175,433 Market Cap 0.00M
02/16/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Feb 12

    Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial

    Read on
  • Feb 08

    Regeneron Reports Fourth Quarter and Full Year 2017 Financial and Operating Results

    Read on

EVENTS

  • Angiogenesis Conference 2018
    Feb 10, 2018

  • Regeneron Pharmaceuticals Q4 2017 Earnings Conference Call
    Feb 8, 2018 | 8:30 AM ET

Events & Presentations

NASDAQ REGN

$332.15 1.03 (0.31)%

High 341.08 Low 328.95 Volume 1,175,433 Market Cap 0.00M
02/16/18 4:00 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information